A study using tau PET 18F-flortaucipir (AV-1451) established that the significantly higher AV-1451 uptake in patients with AD when compared to the patients with probable DLB, along with medial temporal lobe uptake, was able to completely differentiate between AD and probable DLB [21]. This evidence concerns the gene MAPT and Alzheimer disease.